Adragos Pharma, a global CDMO, has completed the acquisition of a commercial-scale sterile fill-finish facility in Maisons-Alfort, France, from Sanofi.

The Maisons-Alfort site is one of Europe’s largest manufacturing facilities for sterile injectables, with industrial-scale capacity for pre-filled syringes (PFS), as well as liquids and lyophilized vials.

The facility is regularly audited by international health authorities, including ANSM (France), NMPA (China), MFDS (South Korea), and ANVISA (Brazil), and supports the global supply of critical injectable medicines.

The Maisons-Alfort site employees are joining Adragos Pharma, helping to ensure full operational continuity while preserving the technical excellence built over the years. This talent integration represents a strategic asset for the site going forward.

This site significantly expands Adragos’ sterile injectables network, adding high-volume pre-filled syringe manufacturing capabilities to its existing vial and ampoule filling operations in Jura, Switzerland, and Livron, France. The combined platform establishes Adragos a leading sterile injectables CDMOs in Europe.

Dr. Andreas Raabe, Founder and CEO of Adragos Pharma, said, “Maisons-Alfort is a landmark acquisition for Adragos and a defining step in our growth journey. We are adding one of Europe’s leading sterile manufacturing sites to our network. Our ambition is clear: to invest, scale, and further develop the site into a top-tier fill-finish platform. This transaction is fully aligned with our strategy to secure and expand highly differentiated pharmaceutical manufacturing capacity in Europe.”